Trade GSK plc shares permanently for 0 euros!
Now on Smartbroker.de
NEW YORK (dpa-AFX Analyzer) – The analysis house Jefferies left the rating for GSK on “Hold” with a price target of 1475 pence after a court ruling on alleged cancer risks of the drug Zantac. The court ruling was positive for the two affected pharmaceutical manufacturers GSK and Sanofi, wrote analyst Peter Welford in a study available on Wednesday. It could be seen as a landmark for US federal lawsuits, particularly in the state of Delaware, where a majority of the lawsuits are pending. Study: 12/06/2022 / 5:13 p.m. / ET Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) WpHG, Art. 20 VO (EU) 596/2014 for the named analyst house can be found at http:/ /web.dpa-afx.de/disclosure/disclosure_compulsory.html.
A notice: ARIVA.DE publishes analyses, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been posted by third parties in the “News” area of this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and/or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.